Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
OMED's Cash to Debt is ranked higher than
79% of the 1438 Companies
in the Global Biotechnology industry.

( Industry Median: 51.73 vs. OMED: No Debt )
OMED' s 10-Year Cash to Debt Range
Min: 290.2   Max: No Debt
Current: No Debt

Equity to Asset 0.31
OMED's Equity to Asset is ranked higher than
54% of the 1086 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. OMED: 0.31 )
OMED' s 10-Year Equity to Asset Range
Min: -1.81   Max: 0.35
Current: 0.31

-1.81
0.35
Interest Coverage No Debt
OMED's Interest Coverage is ranked higher than
57% of the 650 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OMED: No Debt )
OMED' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 1.96
M-Score: 269.13
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -127.97
OMED's Operating margin (%) is ranked higher than
69% of the 1163 Companies
in the Global Biotechnology industry.

( Industry Median: -91.29 vs. OMED: -127.97 )
OMED' s 10-Year Operating margin (%) Range
Min: -161.06   Max: -48.52
Current: -127.97

-161.06
-48.52
Net-margin (%) -126.42
OMED's Net-margin (%) is ranked higher than
68% of the 1163 Companies
in the Global Biotechnology industry.

( Industry Median: -76.91 vs. OMED: -126.42 )
OMED' s 10-Year Net-margin (%) Range
Min: -152.47   Max: -47.87
Current: -126.42

-152.47
-47.87
ROE (%) -51.87
OMED's ROE (%) is ranked higher than
65% of the 1318 Companies
in the Global Biotechnology industry.

( Industry Median: -31.17 vs. OMED: -51.87 )
OMED' s 10-Year ROE (%) Range
Min: -51.43   Max: -51.43
Current: -51.87

ROA (%) -17.40
OMED's ROA (%) is ranked higher than
76% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -25.65 vs. OMED: -17.40 )
OMED' s 10-Year ROA (%) Range
Min: -28.05   Max: -12.61
Current: -17.4

-28.05
-12.61
ROC (Joel Greenblatt) (%) -1019.00
OMED's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 1405 Companies
in the Global Biotechnology industry.

( Industry Median: -346.25 vs. OMED: -1019.00 )
OMED' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1038.97   Max: -385.14
Current: -1019

-1038.97
-385.14
» OMED's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

OMED Guru Trades in Q1 2014

PRIMECAP Management 340,700 sh (unchged)
» More
Q2 2014

OMED Guru Trades in Q2 2014

Jim Simons 59,200 sh (New)
PRIMECAP Management 266,400 sh (-21.81%)
» More
Q3 2014

OMED Guru Trades in Q3 2014

PRIMECAP Management 218,400 sh (-18.02%)
Jim Simons 40,110 sh (-32.25%)
» More
Q4 2014

OMED Guru Trades in Q4 2014

PRIMECAP Management 218,400 sh (unchged)
Jim Simons 20,675 sh (-48.45%)
» More
» Details

Insider Trades

Latest Guru Trades with OMED

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.80
OMED's P/B is ranked higher than
51% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. OMED: 9.80 )
OMED' s 10-Year P/B Range
Min: 3.52   Max: 10.94
Current: 9.8

3.52
10.94
P/S 19.16
OMED's P/S is ranked higher than
62% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 37.00 vs. OMED: 19.16 )
OMED' s 10-Year P/S Range
Min: 1.03   Max: 21.06
Current: 19.16

1.03
21.06
Current Ratio 6.25
OMED's Current Ratio is ranked higher than
79% of the 1401 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. OMED: 6.25 )
OMED' s 10-Year Current Ratio Range
Min: 3.55   Max: 6.25
Current: 6.25

3.55
6.25
Quick Ratio 6.25
OMED's Quick Ratio is ranked higher than
80% of the 1401 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. OMED: 6.25 )
OMED' s 10-Year Quick Ratio Range
Min: 3.55   Max: 6.25
Current: 6.25

3.55
6.25
Days Sales Outstanding 65.72
OMED's Days Sales Outstanding is ranked higher than
83% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 139.31 vs. OMED: 65.72 )
OMED' s 10-Year Days Sales Outstanding Range
Min: 0.22   Max: 65.72
Current: 65.72

0.22
65.72

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.60
OMED's Price/Net Cash is ranked higher than
71% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 109.90 vs. OMED: 12.60 )
OMED' s 10-Year Price/Net Cash Range
Min: 8.63   Max: 10.72
Current: 12.6

8.63
10.72
Price/Net Current Asset Value 11.60
OMED's Price/Net Current Asset Value is ranked higher than
71% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 45.70 vs. OMED: 11.60 )
OMED' s 10-Year Price/Net Current Asset Value Range
Min: 8.41   Max: 9.38
Current: 11.6

8.41
9.38
Price/Tangible Book 10.00
OMED's Price/Tangible Book is ranked higher than
57% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 10.60 vs. OMED: 10.00 )
OMED' s 10-Year Price/Tangible Book Range
Min: 4.22   Max: 9.37
Current: 10

4.22
9.37
Price/Median PS Value 1.80
OMED's Price/Median PS Value is ranked higher than
74% of the 1613 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. OMED: 1.80 )
OMED' s 10-Year Price/Median PS Value Range
Min: 0.42   Max: 1.52
Current: 1.8

0.42
1.52
Earnings Yield (Greenblatt) -10.70
OMED's Earnings Yield (Greenblatt) is ranked higher than
59% of the 1393 Companies
in the Global Biotechnology industry.

( Industry Median: -5.90 vs. OMED: -10.70 )
OMED' s 10-Year Earnings Yield (Greenblatt) Range
Min: -10.7   Max: 0
Current: -10.7

-10.7
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:O0M.Germany,
OncoMed Pharmaceuticals Inc was incorporated in July 2004 in Delaware. The Company is a clinical development-stage biotechnology company focused on discovering and developing first-in-class monoclonal antibody therapeutics targeting cancer stem cells. The Company's operations are based in Redwood City, California. On July 17, 2013, the Company's registration statement on Form S-1 (File No. 333-181331) relating to the initial public offering of its common stock was declared effective by the SEC. The Company has five anti-CSC product candidates in clinical development. Additionally, other antibodies are in preclinical development with Investigational New Drug filings planned for as early as late 2014 or 2015. The first candidate, demcizumab, has completed a single-agent Phase Ia safety and dose escalation trial and is currently in Phase Ib combination therapy trials in patients with non-small cell lung cancer and pancreatic cancer and a Phase Ib/II trial combining demcizumab with paclitaxel in ovarian cancer. The second candidate, anti-Notch2/3 (OMP-59R5), is in a Phase Ib/II trial in pancreatic cancer in combination therapy with gemcitabine and Abraxane and a second Phase Ib/II trial in small cell lung cancer in combination therapy with etoposide and cisplatin chemotherapy. The third candidate, vantictumab (OMP-18R5), continues in a single-agent Phase Ia trial, and the Company has recently initiated three separate Phase Ib combination trials, one trial each in patients with breast cancer, pancreatic cancer, and non-small-cell lung cancer. The fourth candidate, Fzd8-Fc (OMP-54F28), is in a single-agent Phase Ia safety and dose escalation trial in solid tumor malignancies, and has begun three Phase Ib trials, one trial in each of pancreatic cancer, ovarian cancer, and hepatocellular carcinoma, of OMP-54F28 in combination with standard-of-care therapies. The fifth candidate, anti-Notch1 (OMP-52M51), is in two single-agent Phase Ia safety and dose escalation trials in hematologic and solid tumor malignancies.The Company purchases quantities of its product candidates from its contract manufacturers pursuant to purchase orders that it places from time to time. It competes in the segments of the pharmaceutical, biotechnology and other related markets that address solid tumor cancers and hematologic cancers. It also faces competition from many pharmaceutical and biotechnology companies that are also researching and selling products designed to address these markets. The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements on the clinical development, manufacture, marketing and distribution of its product candidates.
» More Articles for OMED

Headlines

Articles On GuruFocus.com
Tumor Drug Takes The Focus At OncoMed Pharmaceuticals Jan 29 2015 

More From Our Partners
Should OncoMed (OMED) Be On Your Radar Now? - Tale of the Tape Apr 7 2015 - ZACKS

More From Other Websites
Nasdaq stocks posting largest percentage decreases Apr 17 2015
OncoMed Presents Demcizumab Data From Phase 1b Clinical Trial in Non-Small Cell Lung Cancer Patients... Apr 16 2015
OncoMed to Present at the Needham Healthcare Conference Apr 09 2015
OncoMed to Present at the Needham Healthcare Conference Apr 09 2015
OncoMed to Present Clinical Data for Demcizumab at the European Lung Cancer Conference Apr 09 2015
OncoMed to Present Clinical Data for Demcizumab at the European Lung Cancer Conference Apr 09 2015
Should OncoMed (OMED) Be On Your Radar Now? - Tale of the Tape Apr 07 2015
OncoMed Collaborates with Eli Lilly for Oncology Candidate - Analyst Blog Apr 06 2015
OncoMed and Lilly Enter Clinical Supply Agreement to Evaluate the Combination of Demcizumab and... Apr 02 2015
OncoMed and Lilly Enter Clinical Supply Agreement to Evaluate the Combination of Demcizumab and... Apr 02 2015
Should OncoMed Pharmaceuticals (OMED) Be On Your Radar Now? - Tale of the Tape Mar 20 2015
ONCOMED PHARMACEUTICALS INC Financials Mar 19 2015
OncoMed to Present Data on Multiple Anti-Cancer Stem Cell Candidates at the American Association of... Mar 19 2015
OncoMed to Present Data on Multiple Anti-Cancer Stem Cell Candidates at the American Association of... Mar 19 2015
OncoMed Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today Mar 12 2015
ONCOMED PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 12 2015
OncoMed Pharmaceuticals Reports Full Year and Fourth Quarter 2014 Financial Results and Recent... Mar 12 2015
OncoMed Pharmaceuticals Reports Full Year and Fourth Quarter 2014 Financial Results and Recent... Mar 12 2015
Q4 2014 OncoMed Pharmaceuticals Inc Earnings Release - After Market Close Mar 12 2015
Drugs and money: Betting big on a biotech giant Mar 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK